These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 25232099)

  • 1. Mechanism of allosteric inhibition of HIV-1 reverse transcriptase revealed by single-molecule and ensemble fluorescence.
    Schauer GD; Huber KD; Leuba SH; Sluis-Cremer N
    Nucleic Acids Res; 2014 Oct; 42(18):11687-96. PubMed ID: 25232099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allosteric suppression of HIV-1 reverse transcriptase structural dynamics upon inhibitor binding.
    Seckler JM; Barkley MD; Wintrode PL
    Biophys J; 2011 Jan; 100(1):144-53. PubMed ID: 21190666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efavirenz binding to HIV-1 reverse transcriptase monomers and dimers.
    Braz VA; Holladay LA; Barkley MD
    Biochemistry; 2010 Jan; 49(3):601-10. PubMed ID: 20039714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-nucleoside Reverse Transcriptase Inhibitors Inhibit Reverse Transcriptase through a Mutually Exclusive Interaction with Divalent Cation-dNTP Complexes.
    DeStefano JJ
    Biochemistry; 2019 Apr; 58(16):2176-2187. PubMed ID: 30900874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical mechanism of HIV-1 resistance to rilpivirine.
    Singh K; Marchand B; Rai DK; Sharma B; Michailidis E; Ryan EM; Matzek KB; Leslie MD; Hagedorn AN; Li Z; Norden PR; Hachiya A; Parniak MA; Xu HT; Wainberg MA; Sarafianos SG
    J Biol Chem; 2012 Nov; 287(45):38110-23. PubMed ID: 22955279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p66/p51 and p51/p51 recombinant forms of reverse transcriptase from human immunodeficiency virus type 1--interactions with primer tRNA(Lys3), initiation of cDNA synthesis, and effect of inhibitors.
    Dufour E; El Dirani-Diab R; Boulmé F; Fournier M; Nevinsky G; Tarrago-Litvak L; Litvak S; Andreola ML
    Eur J Biochem; 1998 Jan; 251(1-2):487-95. PubMed ID: 9492322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The N348I mutation at the connection subdomain of HIV-1 reverse transcriptase decreases binding to nevirapine.
    Schuckmann MM; Marchand B; Hachiya A; Kodama EN; Kirby KA; Singh K; Sarafianos SG
    J Biol Chem; 2010 Dec; 285(49):38700-9. PubMed ID: 20876531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonnucleoside inhibitor binding affects the interactions of the fingers subdomain of human immunodeficiency virus type 1 reverse transcriptase with DNA.
    Peletskaya EN; Kogon AA; Tuske S; Arnold E; Hughes SH
    J Virol; 2004 Apr; 78(7):3387-97. PubMed ID: 15016861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective interaction of the human immunodeficiency virus type 1 reverse transcriptase nonnucleoside inhibitor efavirenz and its thio-substituted analog with different enzyme-substrate complexes.
    Maga G; Ubiali D; Salvetti R; Pregnolato M; Spadari S
    Antimicrob Agents Chemother; 2000 May; 44(5):1186-94. PubMed ID: 10770750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efavirenz binding site in HIV-1 reverse transcriptase monomers.
    Braz VA; Barkley MD; Jockusch RA; Wintrode PL
    Biochemistry; 2010 Dec; 49(49):10565-73. PubMed ID: 21090588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.
    Hu Z; Kuritzkes DR
    J Virol; 2014 Aug; 88(16):9268-76. PubMed ID: 24899199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thumbs down for HIV: domain level rearrangements do occur in the NNRTI-bound HIV-1 reverse transcriptase.
    Wright DW; Sadiq SK; De Fabritiis G; Coveney PV
    J Am Chem Soc; 2012 Aug; 134(31):12885-8. PubMed ID: 22827470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The amino acid Asn136 in HIV-1 reverse transcriptase (RT) maintains efficient association of both RT subunits and enables the rational design of novel RT inhibitors.
    Balzarini J; Auwerx J; Rodríguez-Barrios F; Chedad A; Farkas V; Ceccherini-Silberstein F; García-Aparicio C; Velázquez S; De Clercq E; Perno CF; Camarasa MJ; Gago F
    Mol Pharmacol; 2005 Jul; 68(1):49-60. PubMed ID: 15833734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitors.
    Xu HT; Colby-Germinario SP; Huang W; Oliveira M; Han Y; Quan Y; Petropoulos CJ; Wainberg MA
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5649-57. PubMed ID: 24002090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of HIV reverse transcriptase inhibition by zinc: formation of a highly stable enzyme-(primer-template) complex with profoundly diminished catalytic activity.
    Fenstermacher KJ; DeStefano JJ
    J Biol Chem; 2011 Nov; 286(47):40433-42. PubMed ID: 21953456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The N137 and P140 amino acids in the p51 and the P95 amino acid in the p66 subunit of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase are instrumental to maintain catalytic activity and to design new classes of anti-HIV-1 drugs.
    Auwerx J; Van Nieuwenhove J; Rodríguez-Barrios F; de Castro S; Velázquez S; Ceccherini-Silberstein F; De Clercq E; Camarasa MJ; Perno CF; Gago F; Balzarini J
    FEBS Lett; 2005 Apr; 579(11):2294-300. PubMed ID: 15848161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric human immunodeficiency virus type 1 and feline immunodeficiency virus reverse transcriptases: role of the subunits in resistance/sensitivity to non-nucleoside reverse transcriptase inhibitors.
    Auwerx J; North TW; Preston BD; Klarmann GJ; De Clercq E; Balzarini J
    Mol Pharmacol; 2002 Feb; 61(2):400-6. PubMed ID: 11809865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elucidating the inhibition mechanism of HIV-1 non-nucleoside reverse transcriptase inhibitors through multicopy molecular dynamics simulations.
    Ivetac A; McCammon JA
    J Mol Biol; 2009 May; 388(3):644-58. PubMed ID: 19324058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms.
    Hsiou Y; Ding J; Das K; Clark AD; Hughes SH; Arnold E
    Structure; 1996 Jul; 4(7):853-60. PubMed ID: 8805568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonnucleoside Reverse Transcriptase Inhibitor Hypersusceptibility and Resistance by Mutation of Residue 181 in HIV-1 Reverse Transcriptase.
    Barnard JP; Huber KD; Sluis-Cremer N
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31160281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.